OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding

Recruiting N/A Interventional Study
Upper Gastrointestinal Bleeding
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
236 (estimated)
Sponsor
Chinese University of Hong Kong · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
In the management of patients with acute upper non-variceal upper gastrointestinal bleeding, further bleeding is the most important adverse factor predictive of mortality. In the United Kingdom Audit on acute upper gastrointestinal bleeding, clinical evidence of further bleeding was reported in 13% of patients following the first endoscopy and 27% of them died. The use of OTSC has emerged as an al…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 1\. Patients presented with overt signs of acute upper gastrointestinal bleeding (hematemesis, melena and/or hypotension) 2. documented bleeding lesion at endoscopy (ulcer, dieulafoy's lesion and others), further bleeds (persistent or recurrent) after endoscopic hemostasis (th…
Contacts

Yau Wong James Lau, MD

35052640

laujyw@surgery.cuhk.edu.hk

CONTACT

Yuanyuan yu, phd

35052640

karinayu@surgery.cuhk.edu.hk

CONTACT